Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine.
-
アブストラクト We read with interest the article "Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine" by Baptista et al. [1]. The authors reported the case of a 64-year-old woman treated for multiple sclerosis with 4-aminopyridine (4-AP) who developed severe pulmonary arterial hypertension (PAH) confirmed by right heart catheterization. After initiation of specific PAH therapy and 4-AP discontinuation, a significant hemodynamic improvement was observed with almost hemodynamic normalization (pulmonary vascular resistance < 3 WU) [1]. Interestingly, 5 additional cases of 4-AP-induced PAH have been reported in the worldwide pharmacovigilance database (Vigibase((R)) ). This article is protected by copyright. All rights reserved. ジャーナル名 Fundamental & clinical pharmacology 投稿日 2019/5/31 投稿者 Antigny, Fabrice; Chaumais, Marie-Camille; Humbert, Marc; Montani, David 組織名 Univ. Paris-Sud, Faculte de Medecine, Universite Paris-Saclay, Le Kremlin;Bicetre, France.;AP-HP, Service de Pneumologie, Centre de Reference de l'Hypertension Pulmonaire,;Hopital Bicetre, Le Kremlin Bicetre, France.;Inserm UMR_S 999, Hopital Marie Lannelongue, Le Plessis Robinson, France.;Universite Paris-Sud Saclay, faculte de pharmacie, Chatenay Malabry, France.;AP-HP, service de pharmacie hopital Bicetre, Le Kremlin Bicetre, France. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/31148228/ -
お問合わせ
検索
メルマガ登録
